

Gestational Diabetes Mellitus: A Comprehensive Review On Pathophysiology, Maternal-Fetal Outcomes And Management Strategies

Shravani P. Ghode¹, Parinita D. Hegade², Darshana R. Patil³, Sanika S. Kumbhar⁴, Shradha A. More⁵, Madhura A. Bale⁶, Yashashri R. Dhumal⁷, Amruta S. Ranjane⁸, Sudiksha P. Mohite⁹, Nandini P. Sutar^{10*}

^{1,2,3,4,5,6,7,8,9,10*}Department of Pharmacy-Womens Collage of Pharmacy Peth Vadgaon, Tal. Hatkanangale, Dist.

Kolhapur, Maharashtra – 416112

***Corresponding Author**

Nandini P. Sutar

Department of Pharmacy-Womens Collage of Pharmacy Peth Vadgaon, Tal. Hatkanangale, Dist. Kolhapur, Maharashtra – 416112

Email: nandinisutar04@gmail.com

ABSTRACT

Gestational diabetes mellitus (GDM) is a common metabolic disorder of pregnancy, characterized by glucose intolerance first recognized during gestation, affecting approximately 14% of pregnancies worldwide. Its pathogenesis is multifactorial, arising from an interaction between pre-existing maternal insulin resistance and inadequate pancreatic β -cell compensation, further influenced by genetic predisposition, adipose tissue dysfunction, chronic low-grade inflammation, placental factors, and alterations in the gut microbiome. GDM is associated with significant maternal complications, including hypertensive disorders and an increased long-term risk of type 2 diabetes mellitus (T2DM), as well as adverse fetal and neonatal outcomes such as macrosomia, birth injury, and neonatal hypoglycaemia, with evidence suggesting effects on offspring metabolic and immune health that persist into later life. Despite this progress, key questions regarding early prediction, individualized treatment, and prevention of progression to T2DM remain unresolved. This review synthesizes current knowledge on the pathophysiology, maternal-fetal outcomes, diagnosis, and management of GDM, while highlighting emerging research directions with the potential to improve early identification and long-term outcomes for both mothers and their offspring.

Keyword: Gestational diabetes mellitus; Insulin resistance; Pancreatic β -cell dysfunction; Maternal-fetal outcomes; Placental exosomes; Type 2 diabetes mellitus; Glycaemic management

How to cite this article: Shravani P. Ghode¹ Parinita D. Hegade. Gestational Diabetes Mellitus: A Comprehensive Review On Pathophysiology, Maternal-Fetal Outcomes And Management Strategies. Int J Drug Deliv Technol. 2026;16(84s):822-833. DOI: 10.25258/ijddt.16.84s.91.

INTRODUCTION

Gestational diabetes mellitus (GDM) is a common metabolic disorder of pregnancy characterized by glucose intolerance that is first recognized or diagnosed during gestation. It represents an important maternal and fetal health concern because its effects may extend beyond pregnancy and influence the long-term health of both the mother and offspring[1]. The prevalence of GDM has increased substantially worldwide, paralleling the increasing prevalence of obesity, sedentary lifestyles, advanced maternal age, and other metabolic risk factors. According to International Diabetes Federation estimates cited in the literature, GDM affects approximately 14% of pregnancies worldwide, corresponding to nearly 18.4 million births annually [2]. The development of GDM is closely associated with the physiological insulin resistance that normally develops during pregnancy. As gestation progresses, particularly during the second half of pregnancy, insulin sensitivity decreases as a consequence of hormonal and metabolic adaptations. Placental hormones, including human placental lactogen, oestrogen, progesterone, cortisol, and prolactin, contribute to this physiological reduction in insulin sensitivity [3]. Normally, pancreatic β -cells

compensate by increasing insulin secretion. GDM develops when this compensatory response is inadequate to overcome the increasing insulin resistance, resulting in maternal hyperglycaemia [4].

The pathophysiology of GDM is multifactorial and involves the interaction of maternal genetic predisposition, pre-existing metabolic abnormalities, adipose tissue dysfunction, placental factors, inflammation, and environmental influences. Important risk factors include advanced maternal age, overweight or obesity, family history of GDM or type 2 diabetes mellitus, previous GDM, polycystic ovarian syndrome, hypertension, and unhealthy dietary patterns [5]. These factors may be associated with impaired insulin sensitivity and pancreatic β -cell function, suggesting that pregnancy can unmask underlying metabolic disturbances. Chronic insulin resistance and β -cell dysfunction are therefore considered major components in the pathogenesis of GDM [1].

GDM is associated with a broad range of adverse maternal and fetal outcomes. Maternal complications include hypertensive disorders of pregnancy and an increased likelihood of operative delivery, while fetal and neonatal complications include macrosomia,

increased birth weight, preterm birth, birth injury, and neonatal hypoglycaemia. Evidence also indicates that increasing maternal glucose concentrations are associated with increasing birth weight and other adverse neonatal outcomes [4].

Importantly, the consequences of GDM may persist after delivery. Women with a history of GDM have a substantially increased risk of developing type 2 diabetes mellitus later in life. Similarly, offspring exposed to maternal hyperglycaemia may have increased risks of obesity, impaired glucose tolerance, and other metabolic abnormalities [6]. Recent evidence further suggests that intrauterine exposure to GDM may influence fetal growth, immune development, and early childhood health through alterations in placental function, nutrient transport, inflammation, epigenetic mechanisms, and maternal-neonatal microbiota [5-6].

Management of GDM therefore requires early identification and appropriate glycaemic control to reduce maternal and fetal complications. Screening and diagnostic approaches, dietary modification, physical activity, glucose monitoring, and pharmacological therapy when required form important components of management. Treatment studies have demonstrated that appropriate management can reduce adverse perinatal outcomes [7]. Consequently, understanding the underlying pathophysiology, identifying maternal-fetal consequences, and implementing effective management strategies are essential for improving pregnancy outcomes and reducing the long-term metabolic burden associated with GDM. This comprehensive review focuses on the pathophysiological mechanisms of GDM, its maternal and fetal outcomes, and current approaches to screening, prevention, and management [8].

Epidemiology




Fig. 1: Epidemiology of Gestational Diabetes Mellitus (GDM).

Gestational diabetes mellitus (GDM) is one of the most common metabolic complications of pregnancy, and its prevalence has increased substantially worldwide. The epidemiology of GDM varies considerably among populations because of differences in ethnicity, maternal

age, body weight, lifestyle, genetic susceptibility, diagnostic criteria, and screening practices. According to the 2017 estimates of the International Diabetes Federation (IDF), GDM affects approximately 14% of pregnancies worldwide, corresponding to nearly 18.4 million births annually. These figures demonstrate the considerable global burden of GDM and its importance as a public health concern [7-9].

In the United States, GDM has been reported to occur in approximately 5–9% of pregnancies, with prevalence showing an increasing trend. Differences in reported prevalence between countries and populations may partly reflect variations in screening strategies and diagnostic thresholds. The condition is influenced by several maternal and environmental factors [10]. Advanced maternal age, overweight and obesity, a westernised diet, hypertension, family history of GDM or type 2 diabetes mellitus (T2DM), previous GDM, and polycystic ovarian syndrome are recognized risk factors. Ethnicity and the intrauterine environment may also contribute to differences in susceptibility between populations [11].

The increasing prevalence of GDM parallels the growing prevalence of obesity, sedentary lifestyles, and metabolic disorders among women of reproductive age. Epidemiological evidence also indicates an important relationship between GDM and future maternal metabolic health. Insulin resistance and β -cell dysfunction, which are central features of GDM, may exist before pregnancy and can contribute to an increased risk of developing T2DM after pregnancy [12]. Studies cited in the uploaded literature report that the risk of subsequent T2DM among women with previous GDM may range from 17% to 63% within 15 years, highlighting the long-term epidemiological significance of the disorder [13].

Overall, the substantial and increasing global prevalence of GDM, together with its association with maternal risk factors and future metabolic disease, emphasizes the need for effective screening, early diagnosis, and appropriate management during pregnancy [14].

Risk Factors




Fig. 2: Risk factors associated with Gestational Diabetes Mellitus (GDM).

The development of gestational diabetes mellitus (GDM) is influenced by a combination of maternal, genetic,

environmental, metabolic, and pregnancy-related factors. The uploaded literature indicates that GDM results from the interaction between maternal predisposition and pregnancy-associated metabolic changes. In particular, impaired insulin sensitivity and inadequate pancreatic β -cell compensation are important underlying factors that increase susceptibility to GDM [15].

Advanced maternal age is an important risk factor for GDM. Increasing maternal age is associated with greater metabolic susceptibility and impaired glucose regulation. Overweight and obesity are also strongly associated with GDM because excess adiposity is linked with insulin resistance and abnormal metabolic function. The literature further identifies a westernised diet and sedentary lifestyle as contributing environmental factors that may increase the risk of developing GDM [16].

A family history of GDM or type 2 diabetes mellitus (T2DM) is another important risk factor, suggesting a contribution of genetic and familial metabolic susceptibility. Women with a previous history of GDM have an increased likelihood of developing GDM in subsequent pregnancies. Similarly, a personal history of polycystic ovarian syndrome (PCOS) is associated with an increased risk because of its relationship with insulin resistance and impaired glucose metabolism [11-13].

Hypertension has also been identified as a risk factor associated with GDM. In addition, ethnicity and the intrauterine environment may influence individual susceptibility. These factors may interact with genetic predisposition, maternal metabolic status, and pregnancy-related physiological changes, producing considerable variation in GDM prevalence among different populations [17].

The uploaded literature also highlights pre-existing abnormalities in insulin resistance and β -cell function. During normal pregnancy, insulin resistance physiologically increases, requiring an appropriate compensatory increase in insulin secretion. Women who already have impaired β -cell function or insulin sensitivity may be unable to compensate adequately, resulting in hyperglycaemia and clinical GDM. Thus, pregnancy may reveal or “unmask” previously latent metabolic abnormalities [18].

Other clinically recognized risk indicators include glycosuria, diabetes in a first-degree relative, previous glucose intolerance, marked obesity, and a previous macrosomic infant. These factors are particularly relevant during antenatal risk assessment and screening [19].

Overall, GDM is a multifactorial disorder in which maternal age, obesity, family and personal metabolic history, lifestyle, ethnicity, hypertension, and underlying insulin resistance or β -cell dysfunction collectively contribute to disease susceptibility. Identification of these risk factors is important for appropriate screening and early intervention [18].

Pathophysiology of Gestational Diabetes Mellitus

Gestational diabetes mellitus (GDM) is a heterogeneous metabolic disorder characterized by glucose intolerance that develops or is first recognized during pregnancy. Its pathophysiology involves a complex interaction between maternal metabolic predisposition, pregnancy-related hormonal changes, pancreatic β -cell dysfunction, insulin resistance, adipose tissue abnormalities, inflammation, and fetoplacental factors. The two major metabolic abnormalities associated with GDM are increased insulin resistance and inadequate pancreatic β -cell compensation. GDM generally develops when the increase in insulin secretion is insufficient to overcome the physiological insulin resistance that normally occurs during pregnancy. Thus, pregnancy can reveal or exacerbate metabolic abnormalities that may have been present before conception [12].

Physiological Insulin Resistance During Pregnancy

Normal pregnancy is accompanied by a progressive reduction in maternal insulin sensitivity, particularly during the second half of gestation. Insulin sensitivity decreases by approximately 50–60% as pregnancy advances in both normoglycaemic women and women who develop GDM. This physiological adaptation helps ensure an adequate supply of glucose and other nutrients to the growing fetus. However, women who develop GDM frequently enter pregnancy with an underlying degree of chronic insulin resistance. The physiological insulin resistance of pregnancy is therefore superimposed on this pre-existing metabolic abnormality, resulting in substantially greater insulin resistance [19-20].

Several pregnancy-associated hormones contribute to this physiological decline in insulin sensitivity. Human placental lactogen (hPL), oestrogen, progesterone, cortisol, and prolactin increase during pregnancy and influence peripheral insulin signalling. These hormonal changes interfere with components of insulin-signalling pathways while simultaneously stimulating adaptations in pancreatic β -cell function. In women who are metabolically susceptible, β -cell compensation may be inadequate, resulting in increased maternal blood glucose concentrations and development of GDM [21].

Insulin Resistance and Impaired Insulin Signalling

Insulin resistance is a central component of GDM pathogenesis. In GDM, the insulin receptor itself is generally not reduced in abundance; instead, abnormalities occur at different stages of the intracellular insulin-signalling pathway. Altered expression or phosphorylation of insulin receptor substrate-1 (IRS-1), phosphatidylinositol 3-kinase (PI3K), and glucose transporter 4 (GLUT4) has been described. Reduced GLUT4 expression or altered cellular localization can decrease insulin-mediated glucose uptake in skeletal muscle and adipose tissue. Reduced expression of peroxisome proliferator-activated receptor- γ (PPAR- γ) and increased expression of membrane glycoprotein PC-1 have also been associated with insulin resistance [22]. The JCI article similarly describes exaggerated resistance to insulin-stimulated glucose utilization and

impaired suppression of glucose production and fatty acid levels in women with GDM. These abnormalities indicate that insulin resistance affects several metabolic tissues rather than being restricted to a single organ. Changes in insulin signalling and glucose transport in skeletal muscle and adipose tissue may therefore contribute substantially to maternal hyperglycaemia [23].

Pancreatic β -Cell Dysfunction

The second major component of GDM pathophysiology is pancreatic β -cell dysfunction. Under normal pregnancy conditions, increasing insulin resistance is accompanied by adaptive increases in β -cell activity and insulin secretion. In susceptible women, however, β -cell function is insufficient relative to the degree of insulin resistance. Consequently, insulin production cannot adequately compensate for the increased metabolic requirement, resulting in persistent maternal hyperglycaemia. The uploaded literature identifies β -cell dysfunction as a critical component shared by GDM and type 2 diabetes mellitus (T2DM) [24].

Importantly, β -cell dysfunction may precede pregnancy rather than developing exclusively as a consequence of pregnancy. Studies described in the JCI article demonstrate that women with GDM have impaired β -cell function when insulin secretion is considered relative to their degree of insulin resistance. The majority of women with GDM appear to have β -cell dysfunction occurring on a background of chronic insulin resistance. Therefore, the development of GDM can be viewed as the failure of pancreatic compensation in the face of increasing insulin requirements during pregnancy [25-26].

Genetic and Metabolic Predisposition

Genetic susceptibility contributes to the development of GDM. Several susceptibility genes associated with T2DM have also been linked with GDM, suggesting considerable overlap between the genetic mechanisms of these disorders. Many of these genes are involved in pancreatic β -cell function, including KCNJ11, KCNQ1, MTNR1B, IGF2BP2, and CDKAL1. Other genetic variants associated with insulin resistance and abnormal glucose utilization, including PPARG, TCF7L2, GCK, and GCKR, have also been associated with GDM risk [27].

The JCI article further indicates that β -cell dysfunction can occur in different settings, including autoimmune, monogenic, and insulin-resistance-associated conditions. Mutations affecting genes such as glucokinase and hepatocyte nuclear factor 1 α have been identified in a small proportion of women with GDM. These findings demonstrate that GDM is metabolically heterogeneous and may arise through different mechanisms in different individuals [28].

Adipose Tissue Dysfunction, Lipotoxicity and Inflammation

Adipose tissue plays an important role in the metabolic abnormalities of GDM. Obesity and adipose tissue dysfunction are associated with increased insulin resistance, altered adipokine secretion, lipolysis,

elevated free fatty acids, and chronic low-grade inflammation. Women with GDM have been reported to show increased circulating leptin and inflammatory markers such as tumour necrosis factor- α (TNF- α) and C-reactive protein, together with reduced adiponectin concentrations. Increased lipid accumulation in tissues such as liver and skeletal muscle may further contribute to metabolic dysfunction [24].

The uploaded review identifies chronic low-grade inflammation as an important mechanism linking adipose tissue dysfunction with insulin resistance. Proinflammatory mediators including TNF- α , interferon- γ , interleukin-1, and interleukin-6, together with altered adipokines, can interfere with normal metabolic signalling. Adipocyte hypertrophy and death may promote lipotoxicity and further aggravate insulin resistance. Thus, obesity-associated inflammation and altered adipokine signalling may intensify the metabolic disturbances already produced by pregnancy [16].

Role of the Placenta and Fetoplacental Unit

The placenta is an important endocrine and metabolic organ during pregnancy and contributes to the development of insulin resistance. Interaction between maternal insulin and the syncytiotrophoblast may influence cytokine production, contributing to low-grade systemic inflammation. This inflammatory response is increased in obese pregnancies and in women with GDM. However, the relative contribution of maternal adipose tissue and placental tissue to this inflammatory process remains incompletely defined [29].

Placental-derived exosomes may also participate in the pathophysiology of GDM. These extracellular vesicles contribute to maternal immunomodulation and carry biologically active molecules capable of influencing maternal tissues. The concentration of placenta-derived exosomes in maternal plasma has been reported to be increased in women with GDM, and exosomes released from trophoblasts in GDM may promote proinflammatory cytokine responses. These observations suggest that altered placental signalling may contribute to maternal metabolic and inflammatory abnormalities [30-31].

Gut Microbiome and Systemic Insulin Resistance

Alterations in the gut microbiome have also been proposed as a potential contributor to GDM. The uploaded review reports that gut microbial composition in women with GDM resembles patterns observed in individuals with T2DM and related metabolic abnormalities. Changes in bacterial populations may influence intestinal permeability, allowing inflammatory mediators to enter the circulation and potentially promote systemic insulin resistance. Although the precise mechanisms remain uncertain, these findings suggest an additional interaction between intestinal microbiota, inflammation, and maternal metabolism [17].

Overall Pathophysiological Mechanism

Overall, GDM results from the interaction of pre-existing maternal insulin resistance and β -cell

susceptibility with the progressive physiological insulin resistance of pregnancy. Genetic predisposition, obesity, altered adipokines, chronic inflammation, free fatty acids, impaired insulin signalling, placental hormones, and fetoplacental communication collectively contribute to metabolic deterioration. When pancreatic β -cell insulin secretion cannot adequately compensate for the increasing insulin resistance, maternal glucose concentrations rise and GDM becomes clinically apparent. The physiological insulin resistance normally declines rapidly after delivery; however, women who have experienced GDM may retain greater insulin resistance than women without GDM, supporting the concept that pregnancy can unmask underlying metabolic abnormalities [8-9].

Thus, the pathophysiology of GDM is multifactorial rather than attributable to a single molecular defect. The integrated interaction of maternal genetic and metabolic factors, hormonal adaptations, adipose tissue dysfunction, inflammation, pancreatic β -cell impairment, and placental mechanisms ultimately determines whether a pregnant woman maintains normal glucose homeostasis or develops gestational diabetes [31].

Maternal and Fetal Outcomes

Gestational diabetes mellitus (GDM) is associated with a broad range of maternal, fetal, and neonatal consequences. Although the severity of complications varies according to the degree and duration of maternal hyperglycaemia, GDM represents an important pregnancy-related metabolic disorder because its effects extend beyond pregnancy and may influence the long-term health of both the mother and offspring. The available evidence indicates that GDM is not simply a temporary disturbance of glucose metabolism but is associated with metabolic abnormalities that may persist after delivery and may also influence fetal growth and subsequent metabolic health [32].

Maternal Outcomes

One of the major maternal consequences of GDM is the increased risk of developing diabetes after pregnancy. Women with GDM frequently exhibit abnormalities in insulin sensitivity and pancreatic β -cell function, and these abnormalities may persist after delivery. The development of GDM can therefore be regarded as an early manifestation of metabolic dysfunction and as an important marker of future T2DM risk. Historical and longitudinal observations have demonstrated that the degree of glucose intolerance during pregnancy is related to the subsequent risk of diabetes. Consequently, women with a history of GDM represent an important population for postpartum metabolic surveillance and diabetes-prevention strategies.

The underlying metabolic abnormalities are particularly important in determining long-term maternal outcomes. Pregnancy normally produces a progressive reduction in peripheral insulin sensitivity, partly because of increasing concentrations of human placental lactogen, oestrogen, progesterone, cortisol, and prolactin. In

women who develop GDM, insulin secretion may be insufficient to compensate for this physiological insulin resistance. Existing abnormalities in insulin signalling, β -cell function, adipose tissue metabolism, and inflammatory pathways may therefore become more apparent during pregnancy [31-33].

GDM is also associated with abnormalities in adipokines and inflammatory mediators. Reduced adiponectin and increased leptin and inflammatory markers have been reported in association with GDM. Low adiponectin concentrations during pregnancy have been linked with postpartum insulin resistance, β -cell dysfunction, and abnormal fasting glycaemia. These observations suggest that maternal metabolic abnormalities may continue beyond the immediate postpartum period and contribute to the later development of T2DM [24].

Maternal obesity and pre-existing metabolic dysfunction may further increase the risk of adverse outcomes. Obesity is closely associated with chronic low-grade inflammation and insulin resistance, both of which are important components of GDM pathophysiology. Alterations in adipose tissue, inflammatory signalling, lipid metabolism, and oxidative stress may interact with pregnancy-associated metabolic changes and contribute to maternal complications. The available evidence also indicates that GDM is influenced by a combination of maternal, genetic, environmental, and fetoplacental factors rather than by hyperglycaemia alone [28].

Another important maternal consideration is recurrence in subsequent pregnancies. A previous history of GDM identifies women at increased metabolic risk and may be associated with an increased likelihood of developing GDM again in a future pregnancy. Therefore, long-term follow-up should include appropriate glucose assessment, weight management, dietary modification, physical activity, and monitoring for the development of diabetes. Earlier clinical evidence also emphasized the importance of postpartum lifestyle measures, including regular exercise and dietary modification, for reducing future metabolic risk [34].

Fetal Outcomes

Maternal hyperglycaemia can substantially influence the intrauterine environment and fetal growth. Glucose crosses the placenta, whereas maternal insulin does not, resulting in increased fetal exposure to glucose when maternal blood glucose concentrations are elevated. The fetal metabolic response may include increased insulin secretion, which can promote growth and fat deposition. Consequently, excessive fetal growth or macrosomia has historically been recognized as an important complication associated with maternal diabetes and GDM.

The uploaded literature indicates that diagnosis of GDM identifies pregnancies at increased risk of perinatal morbidity as well as long-term obesity and glucose intolerance in offspring. Thus, the effects of GDM may begin during fetal development and extend into later life. The intrauterine environment created by maternal metabolic abnormalities may contribute to persistent

alterations in offspring adiposity and glucose metabolism.

Fetal overgrowth is clinically important because increased fetal size can complicate delivery. Macrosomia may increase the likelihood of difficult delivery and birth trauma, including shoulder dystocia and associated neonatal injuries. The clinical literature included in the uploaded material identifies macrosomia as an important adverse outcome and emphasizes the relationship between maternal glycaemic control and fetal growth. However, the evidence regarding elective early delivery solely to prevent complications associated with fetal overgrowth has been limited. One randomized trial reported that earlier delivery reduced macrosomia but did not demonstrate reductions in brachial plexus injury, neonatal hypoglycaemia, or clavicle fractures.

Neonatal hypoglycaemia is another important consequence of maternal diabetes. When the fetus is chronically exposed to increased maternal glucose, fetal insulin secretion may increase. After birth, the maternal glucose supply is suddenly interrupted while neonatal insulin concentrations may remain elevated, predisposing the newborn to hypoglycaemia. This complication emphasizes the importance of appropriate maternal glycaemic management during pregnancy and neonatal monitoring after delivery.

In addition to macrosomia and hypoglycaemia, pregnancies complicated by GDM may be associated with other adverse perinatal outcomes. The uploaded clinical literature discusses increased risks of complications such as preterm birth and the need for increased fetal surveillance in pregnancies with inadequate glycaemic control or requiring pharmacological treatment. Maternal metabolic control therefore remains an important determinant of fetal and neonatal well-being [31-34].

Placental and Developmental Effects

The placenta represents an important biological interface between maternal metabolism and fetal development. GDM is associated with changes in placental function, inflammatory signalling, and extracellular communication. Placental-derived exosomes are involved in maternal immunomodulation and may influence endothelial and metabolic responses. Their concentration has been reported to be increased in women with GDM during early pregnancy, while exosomes released from trophoblasts may stimulate proinflammatory cytokine secretion. Such alterations could influence the maternal-fetal environment and contribute to complications associated with GDM.

Alterations in adipokines and inflammatory pathways may also affect fetal development. Changes in maternal adiponectin, leptin, inflammatory mediators, and lipid metabolism can influence placental nutrient handling and the intrauterine environment. Placental adiponectin gene methylation has also been associated with maternal blood glucose concentrations, suggesting that epigenetic mechanisms may contribute to the relationship between maternal metabolic status and fetal development [34-35].

Long-Term Offspring Outcomes

The consequences of GDM may extend beyond the neonatal period. Previous studies cited in the uploaded literature have associated exposure to the GDM intrauterine environment with increased offspring adiposity, obesity, and glucose intolerance later in life. These observations support the concept of developmental or metabolic programming, whereby maternal metabolic disturbances during pregnancy may influence the future metabolic phenotype of the child.

The developing evidence also suggests that GDM may influence other aspects of offspring health. Alterations in placental function, inflammatory signalling, epigenetic regulation, and the developing metabolic environment are potential mechanisms through which maternal GDM could affect offspring development. However, the precise contribution of each mechanism remains incompletely understood and requires further longitudinal investigation [36].

Diagnosis of Gestational Diabetes Mellitus

Diagnosis of gestational diabetes mellitus (GDM) is based primarily on the identification of abnormal maternal glucose metabolism during pregnancy. GDM is defined as glucose intolerance of varying severity with onset or first recognition during pregnancy. Because GDM may remain asymptomatic, systematic screening is important for identifying women with abnormal glucose regulation and reducing the potential maternal and fetal consequences associated with untreated hyperglycaemia [9].

The diagnostic approach generally begins with clinical risk assessment. Maternal characteristics and previous obstetric or metabolic history are considered to identify women who may have an increased likelihood of GDM. The uploaded literature identifies marked obesity, diabetes in first-degree relatives, a personal history of glucose intolerance or GDM, previous delivery of a macrosomic infant, and current glycosuria as important high-risk characteristics. Women without these high-risk features may undergo screening according to their overall risk profile [31].

For women at average risk, glucose screening is generally performed during the period when pregnancy-related insulin resistance becomes more pronounced. The provided article describes blood glucose screening between 24 and 28 weeks of gestation for women with average clinical risk. High-risk women may require earlier assessment during the initial antenatal visit, with repeat testing at 24-28 weeks if GDM has not already been identified.

A 50-g oral glucose challenge test can be used as an initial screening procedure. According to the uploaded article, a venous serum or plasma glucose concentration of ≥ 140 mg/dL (7.8 mmol/L) identifies women who require further diagnostic evaluation, while a lower threshold of ≥ 130 mg/dL (7.2 mmol/L) increases the sensitivity of screening. Women with positive screening results are subsequently evaluated using a diagnostic oral glucose tolerance test (OGTT) [24, 32].

Clinical risk assessment also recognizes low-risk women in whom routine glucose screening may not be required according to the criteria described in the source. These characteristics include age below 25 years, low-risk ethnicity, normal prepregnancy weight and pregnancy weight gain, absence of diabetes in first-degree relatives, no previous abnormal glucose levels, and no prior poor obstetric outcomes.

Overall, diagnosis of GDM involves risk assessment followed by glucose screening and confirmatory diagnostic testing when indicated. Early identification is particularly important because GDM may reflect previously unrecognized metabolic abnormalities and because its development is closely associated with insulin resistance and β -cell dysfunction [3,19].

Management

The management of gestational diabetes mellitus (GDM) is primarily directed toward achieving adequate glycemic control while minimizing maternal and fetal complications. Evidence presented in the reviewed literature indicates that active management of GDM can improve pregnancy outcomes. Treatment generally involves regular blood glucose monitoring, medical nutritional therapy, physical activity, pharmacological intervention when required, fetal surveillance, appropriate intrapartum management, and postpartum follow-up. The overall objective is to maintain maternal glucose levels within an acceptable range and reduce complications associated with maternal hyperglycemia [17].

Glucose Monitoring

Regular monitoring of maternal blood glucose is an important component of GDM management. The reviewed article recommends assessment of fasting glucose together with postprandial glucose measurements, generally at one or two hours after meals. This approach provides information regarding the patient's glycemic profile and helps determine whether dietary modification alone is sufficient or whether pharmacotherapy is required. The article reports treatment targets of fasting glucose below approximately 96 mg/dL, one-hour postprandial glucose below 140 mg/dL, and two-hour postprandial glucose below 120–127 mg/dL [8].

Medical Nutritional Therapy

Dietary modification is considered the first-line treatment for women diagnosed with GDM. Medical nutritional therapy should preferably be planned with an experienced nutritionist and should consider the individual's cultural and dietary preferences. Dietary programs commonly involve carbohydrate counting and meal- and snack-specific recommendations. The nutritional plan may be modified according to the patient's glucose measurements, weight gain, food preferences, and adequacy of caloric intake. An important consideration is avoiding excessive dietary restriction, particularly when it results in inadequate maternal weight gain or persistent hunger [17].

Physical Activity

Moderate exercise may provide an additional approach for improving glycemic management in women with GDM. The reviewed article describes moderate physical activity as a safe, practical, and inexpensive intervention. Exercise is generally considered alongside nutritional modification and glucose monitoring rather than as an isolated treatment strategy. However, the article also notes that the effect of nutritional therapy and exercise on clinical outcomes had not been conclusively demonstrated in large randomized controlled trials at the time of publication [25].

Pharmacological Therapy

Pharmacological treatment is considered when adequate glycemic control cannot be achieved through medical nutritional therapy alone. Indications include persistent hyperglycemia, elevated fasting glucose, inadequate expected weight gain related to dietary restriction, or persistent hunger. The reviewed article reports that insulin therapy was recommended when fasting glucose exceeded 95 mg/dL, one-hour postprandial glucose exceeded approximately 130–140 mg/dL, or two-hour postprandial glucose exceeded 120 mg/dL.

Insulin was described as the mainstay and first-line pharmacological treatment for GDM. Common regimens included intermediate-acting insulin such as neutral protamine Hagedorn (NPH) and short-acting preparations such as regular insulin, aspart, or lispro. NPH was identified as the intermediate-acting insulin of choice in the reviewed article. Insulin dosage was individualized according to factors such as prepregnancy body mass index, glucose concentrations, and lifestyle [27].

Oral antidiabetic agents were also discussed as possible alternatives. Glyburide demonstrated effectiveness and probable safety in the studies reviewed, although the article emphasized uncertainty concerning its absolute safety and placental transfer. It was considered an alternative for women unable or unwilling to use insulin. Metformin was another potential option; in the MiG trial discussed in the article, metformin was used with additional insulin when required, and 46% of women receiving metformin also required insulin therapy. The article also highlighted that metformin crosses the placenta, indicating the need for careful consideration of its use during pregnancy [33].

Fetal Surveillance and Antenatal Care

Fetal monitoring forms an important part of management, particularly in women requiring pharmacotherapy or those with poor metabolic control. Antenatal surveillance may include ultrasonography, assessment of fetal growth and estimated fetal weight, nonstress testing, and evaluation of amniotic fluid. The frequency of monitoring is influenced by the degree of maternal glycemic control, treatment modality, and the presence of additional risk factors such as hypertension. For women receiving insulin or those with poor glucose control, the reviewed article describes twice-weekly nonstress testing and amniotic fluid assessment beginning in the third trimester [36].

Intrapartum Management and Delivery

During labor, women with diet-controlled GDM generally do not require intensive glucose management, although measurement of blood glucose on admission is advisable. Women receiving pharmacological therapy require more frequent glucose monitoring, traditionally at approximately hourly intervals. The reviewed article notes that although intravenous insulin and dextrose-containing solutions were historically used, many women requiring insulin remain euglycemic during labor and may not require active insulin management.

The timing and mode of delivery should be individualized because definitive evidence regarding elective delivery in GDM was limited in the reviewed article. Fetal macrosomia is an important consideration because of its association with adverse maternal and neonatal outcomes. Studies discussed in the article showed that earlier delivery could reduce macrosomia but did not clearly reduce complications such as brachial plexus injury, neonatal hypoglycemia, or clavicular fracture. Therefore, decisions concerning induction or cesarean delivery should consider maternal and fetal status [29].

Postpartum Management

Postpartum follow-up is essential because women with a history of GDM have an increased risk of developing type 2 diabetes mellitus. Most women do not require insulin after delivery, although glucose assessment before hospital discharge is considered appropriate. The reviewed article recommends continued diabetes screening at regular intervals and emphasizes lifestyle modification. Postpartum strategies include breastfeeding, moderate physical activity, and dietary modification aimed at achieving appropriate weight management and reducing future diabetes risk [30].

Overall, effective management of GDM requires an integrated approach combining glucose monitoring, individualized nutritional therapy, physical activity, pharmacological treatment when necessary, fetal surveillance, appropriate delivery planning, and long-term postpartum follow-up. Evidence from the reviewed article indicates that treatment of GDM can reduce adverse perinatal outcomes, supporting the importance of timely diagnosis and active glycemic management [36].

Recent Advances

Recent advances in the understanding and management of gestational diabetes mellitus (GDM) have shifted the disease concept from a transient disorder of pregnancy-associated hyperglycemia toward a complex metabolic condition involving maternal insulin resistance, pancreatic β -cell dysfunction, placental biology, inflammation, fetal programming, and long-term maternal and offspring health. Earlier literature primarily emphasized diagnosis, glucose monitoring, dietary modification, exercise, insulin therapy, fetal surveillance, and postpartum diabetes screening. More recent evidence has expanded this perspective by identifying potential biomarkers, molecular

mechanisms, placental factors, gut microbiome alterations, individualized treatment approaches, and longer-term consequences for the offspring.

Advances in Understanding the Pathophysiology

One important advance is the recognition that GDM does not result from a single metabolic abnormality. Pregnancy normally produces a progressive reduction in peripheral insulin sensitivity, influenced by hormones such as human placental lactogen, estrogen, progesterone, cortisol, and prolactin. In healthy pregnancy, pancreatic β -cells compensate by increasing insulin secretion. GDM develops when this compensatory response is insufficient to overcome pregnancy-associated insulin resistance. Recent mechanistic research has therefore emphasized the interaction between pre-existing metabolic susceptibility and physiological changes occurring during pregnancy. Molecular studies have further identified abnormalities in insulin-signalling pathways, including defects involving insulin receptor phosphorylation, insulin receptor substrate-1, phosphatidylinositol 3-kinase, and GLUT4 expression. Changes in adipokines and inflammatory mediators, including leptin, adiponectin, and proinflammatory cytokines, are also increasingly recognized as contributors to insulin resistance. These findings provide a mechanistic basis for investigating more individualized approaches to GDM prevention and treatment.

Placental Exosomes and MicroRNAs as Emerging Biomarkers

The fetoplacental unit has become an important area of GDM research. Placental-derived exosomes are extracellular vesicles involved in maternal-fetal communication and immunological adaptation during pregnancy. The uploaded review reports that circulating placental-derived exosomes may be increased as early as 11–14 weeks of gestation in women who subsequently develop GDM. These exosomes can influence endothelial and inflammatory responses, suggesting their potential value as early indicators of abnormal pregnancy metabolism.

MicroRNAs are another emerging area of investigation. Changes in specific microRNAs have been associated with GDM-related inflammatory and metabolic pathways. For example, the uploaded article describes an association between increased miR-326 and reduced adiponectin, suggesting a possible connection between altered post-transcriptional regulation, inflammation, and insulin resistance. However, findings for individual microRNAs have not been consistent across studies. Consequently, microRNA-based diagnosis remains investigational, but these molecules may eventually contribute to multi-marker prediction models for early identification of GDM.

Biomarker-Based Prediction and Early Detection

Another important advance is the search for biomarkers capable of predicting GDM before conventional glucose-based diagnosis. The uploaded literature identifies several potential biological indicators associated with

GDM, including adipokines, inflammatory markers, adipocyte fatty-acid binding protein, oxidative-stress-related factors, and other metabolic mediators. Studies have also investigated circulating and placental markers that may reflect altered insulin sensitivity or placental dysfunction.

The possibility of identifying high-risk women earlier in pregnancy is clinically important because conventional screening commonly occurs during the second trimester. Earlier identification could allow nutritional, behavioral, and metabolic interventions to begin before substantial hyperglycemia develops. Nevertheless, individual biomarkers have not yet demonstrated sufficient consistency to replace established glucose-based diagnostic approaches. Therefore, future advances are likely to involve combinations of clinical characteristics, biochemical markers, and molecular signatures rather than dependence on a single biomarker.

Gut Microbiome and Metabolic Research

The maternal gut microbiome has also emerged as a potential contributor to GDM pathogenesis. The uploaded review reports that women with GDM exhibit changes in gut microbial composition that resemble alterations observed in individuals with type 2 diabetes. Changes involving bacterial populations and increased intestinal permeability may facilitate movement of inflammatory mediators into the systemic circulation, potentially contributing to insulin resistance.

These findings have generated interest in microbiome-based approaches for prediction and prevention. Although microbiome research is still developing, future strategies may include dietary interventions, targeted probiotics or prebiotics, and other approaches designed to modify microbial composition and metabolic activity. At present, however, the available evidence is insufficient to establish microbiome manipulation as a standard treatment for GDM.

Advances in Pharmacological Management

Pharmacological management has also evolved. The uploaded management article identified insulin as the mainstay of pharmacological treatment while discussing glyburide and metformin as possible alternatives. Insulin therapy remains important because it can be individually adjusted according to fasting and postprandial glucose concentrations. The article also highlighted increasing interest in oral agents, particularly metformin, although placental transfer and long-term fetal safety were recognized as important considerations.

Contemporary evidence has further refined this discussion. Current clinical standards continue to place lifestyle modification at the foundation of treatment and recommend insulin when glycemic targets are not achieved. Metformin and glyburide remain subjects of international debate because both cross the placenta and long-term effects on offspring require consideration.

Metformin is particularly important in current research. A recent comprehensive review describes potential benefits including reduced gestational weight gain, neonatal hypoglycemia, and macrosomia, while also

emphasizing heterogeneity among studies and uncertainty regarding long-term offspring effects. This has encouraged research into whether treatment should be individualized according to maternal obesity, ethnicity, disease severity, timing of diagnosis, and other patient characteristics rather than applying a uniform pharmacological strategy.

Digital Health and Telemedicine

Digital health represents another important development in GDM care. Smartphone applications, telemedicine consultations, remote glucose reporting, and digital dietary support can improve communication between patients and healthcare professionals. Contemporary evidence suggests that combining telehealth with conventional clinical visits may improve pregnancy outcomes compared with standard in-person care alone. These approaches may be particularly valuable for improving adherence to glucose monitoring and lifestyle interventions. Digital platforms can facilitate frequent review of glucose values, dietary patterns, physical activity, and treatment response without requiring every interaction to occur through a hospital visit. However, accessibility, digital literacy, privacy, and healthcare-resource limitations remain important considerations.

Continuous Glucose Monitoring and Personalized Care Continuous glucose monitoring (CGM) and other glucose-monitoring technologies represent a major direction in diabetes care. These technologies provide more detailed information regarding glucose fluctuations than occasional finger-stick measurements. Current research is investigating how technology can support individualized management during pregnancy and improve recognition of periods of hyperglycemia or hypoglycemia. Recent technology-focused literature emphasizes that diabetes technology is advancing rapidly, although pregnancy-specific limitations and the need for individualized use remain.

For GDM specifically, the future potential of CGM lies in identifying postprandial glucose excursions and patterns that may not be captured by conventional intermittent testing. Integration of CGM data with dietary and clinical information may eventually support more precise adjustment of nutritional and pharmacological therapy.

Early GDM and Timing of Intervention

Another major recent development is increased attention to GDM occurring earlier than the conventional 24–28-week screening period. The 2024 Lancet series reported that a substantial proportion of GDM is diagnosed in early pregnancy and highlighted the importance of distinguishing early-onset disease from GDM developing later in pregnancy. The evidence also suggests that the benefits of treating early GDM are not yet completely resolved, emphasizing the need for further randomized controlled trials.

A 2025 systematic review and meta-analysis of randomized trials similarly concluded that early detection and treatment before 20 weeks did not yet demonstrate unequivocal benefits across all outcomes,

with the quality of evidence for many outcomes being low or very low. This represents an important research gap rather than a settled clinical question.

Advances in Understanding Long-Term Offspring Effects

Recent research has increasingly focused on consequences extending beyond birth. The uploaded 2025 multicenter longitudinal cohort study reported that infants born to mothers with GDM had higher weight-for-age scores and greater susceptibility to food allergy at six months of corrected age compared with infants born after normal glucose tolerance. The study suggests that GDM may influence fetal growth trajectories and early immune development, although further research is required to establish causal mechanisms.

The same study proposes that maternal hyperglycemia may affect placental function, nutrient transport, inflammatory signaling, epigenetic regulation, and maternal or neonatal gut microbiota. These mechanisms could contribute to long-term developmental and immune outcomes in exposed offspring.

Future Perspectives

Gestational diabetes mellitus (GDM) represents a complex metabolic disorder resulting from interactions among genetic, environmental, maternal, placental, and fetal factors. Although substantial progress has been made in understanding its pathophysiology, important questions regarding disease prediction, prevention, individualized treatment, and long-term consequences remain unresolved. Future research should therefore move beyond conventional glucose-based diagnosis and focus on identifying the molecular and metabolic mechanisms that determine susceptibility to GDM and its progression to type 2 diabetes mellitus (T2DM). The available evidence indicates that GDM provides an important opportunity to investigate early abnormalities in glucose metabolism and to develop preventive strategies for both mothers and their offspring.

One important future direction is the development of reliable biomarkers for the early prediction of GDM. Current research has identified several potentially useful markers, including adiponectin, leptin, inflammatory mediators, adipocyte fatty acid-binding protein, and other adipokines. In particular, reduced adiponectin concentrations during pregnancy have been associated with subsequent insulin resistance, β -cell dysfunction, and abnormal fasting glycaemia. However, these biomarkers require further validation before they can be incorporated into routine clinical screening. Future studies should evaluate combinations of metabolic, inflammatory, hormonal, and genetic markers rather than relying on a single biomarker.

Placental biology and extracellular communication also represent promising areas for future investigation. Placenta-derived exosomes are involved in maternal immunomodulation and may influence metabolic adaptation during pregnancy. Their concentration has been reported to be increased in women with GDM during early pregnancy, while trophoblast-derived

exosomes may stimulate proinflammatory cytokine production. Similarly, altered microRNA expression, including associations involving miR-326 and adiponectin, may contribute to the inflammatory and metabolic abnormalities of GDM. Nevertheless, results for individual microRNAs as diagnostic biomarkers have been inconsistent. Further large-scale and standardized studies are required to determine whether exosomes and microRNAs can provide clinically useful tools for early prediction, disease classification, or monitoring of treatment response.

Genetic and gene–environment interactions should receive greater attention in future research. Existing evidence suggests that susceptible genetic variants may influence β -cell function and insulin sensitivity, but the precise contribution of individual genetic factors remains incompletely understood. Future genetic studies may help identify women whose pancreatic β -cells are unable to compensate adequately for pregnancy-associated insulin resistance. Investigation of interactions between genetic susceptibility, obesity, diet, physical activity, and other environmental factors could permit more accurate identification of women at high risk of GDM. Such knowledge may ultimately support personalized prevention and treatment strategies.

The gut microbiome is another emerging research area. Women with GDM have been reported to show alterations in gut microbial composition during and after pregnancy. Increased intestinal permeability and changes in microbial populations may facilitate the movement of inflammatory mediators into the circulation and contribute to systemic insulin resistance. However, the mechanisms linking specific microorganisms, intestinal permeability, inflammation, and glucose metabolism remain uncertain. Future longitudinal and intervention studies are required to determine whether modification of the gut microbiome can prevent GDM or improve metabolic outcomes.

Future management should increasingly focus on preventing the transition from GDM to T2DM. Women with previous GDM may retain insulin resistance and β -cell dysfunction after pregnancy, making postpartum metabolic surveillance particularly important. Earlier studies suggest that interventions directed at improving insulin sensitivity may help preserve pancreatic β -cell function and reduce diabetes risk. Therefore, long-term follow-up, lifestyle modification, appropriate weight management, and individualized metabolic monitoring should become integral components of GDM care rather than limiting treatment to pregnancy alone.

Finally, greater attention should be given to the long-term health of offspring exposed to GDM. Previous evidence links the intrauterine environment associated with maternal GDM to later obesity and glucose intolerance, while recent research has also reported associations with altered infant growth and increased susceptibility to food allergy. Further longitudinal studies are needed to clarify how maternal hyperglycaemia, placental dysfunction, inflammatory

pathways, and metabolic programming influence offspring health across childhood and adulthood.

CONCLUSION:

Gestational diabetes mellitus is a multifactorial metabolic disorder of pregnancy arising from the interaction between pre-existing maternal insulin resistance, inadequate pancreatic β -cell compensation, genetic susceptibility, adipose tissue dysfunction, chronic inflammation, and placental factors. Its impact extends well beyond the antenatal period, carrying significant short-term maternal and fetal risks-including hypertensive disorders, macrosomia, birth injury, and neonatal hypoglycaemia-as well as long-term consequences such as an elevated maternal risk of type 2 diabetes mellitus and increased susceptibility to obesity and metabolic dysfunction in offspring. Timely risk assessment, systematic screening, and a comprehensive management approach combining glucose monitoring, nutritional therapy, physical activity, and pharmacological treatment when necessary have been shown to meaningfully reduce adverse perinatal outcomes.

Despite considerable progress in understanding the pathophysiology and clinical management of GDM, important gaps remain. The role of emerging biomarkers such as placental exosomes and microRNAs, the contribution of the gut microbiome, the optimal timing and benefit of early intervention, and the long-term implications for offspring health are areas that require further, well-designed longitudinal and interventional research. Advances in digital health, telemedicine, and continuous glucose monitoring offer promising avenues for more individualized and accessible care. Ultimately, a shift toward earlier prediction, personalized treatment strategies, and sustained postpartum surveillance is essential-not only to improve immediate pregnancy outcomes but also to mitigate the long-term metabolic burden of GDM on both mothers and their children.

REFERENCES:

1. Bao W, Bowers K, Tobias DK et al (2014) Prepregnancy low carbohydrate dietary pattern and risk of gestational diabetes mellitus: a prospective cohort study. *Am J Clin Nutr* 99:1378–1384.
2. Zhang C, Schulze MB, Solomon CG, Hu FB (2006) A prospective study of dietary patterns, meat intake and the risk of gestational diabetes mellitus. *Diabetologia* 49:2604–2613.
3. Bao W, Tobias DK, Hu FB, Chavarro JE, Zhang C (2016) Pre pregnancy potato consumption and risk of gestational diabetes mellitus: prospective cohort study. *BMJ* 352:h6898.
4. Tobias DK, Zhang C, Chavarro J et al (2012) Prepregnancy adherence to dietary patterns and lower risk of gestational diabetes mellitus. *Am J Clin Nutr* 96:289–295.
5. Zhang C, Liu S, Solomon CG, Hu FB (2006) Dietary fiber intake, dietary glycemic load, and the risk for gestational diabetes mellitus. *Diabetes Care* 29:2223–2230.
6. Zhang C, Tobias DK, Chavarro JE et al (2014) Adherence to healthy lifestyle and risk of gestational diabetes mellitus: prospective cohort study. *BMJ* 349:g5450.
7. Tuomilehto J, Lindstrom J, Eriksson JG et al (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med* 344:1343–1350.
8. Ratner RE, Christophi CA, Metzger BE et al (2008) Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. *J Clin Endocrinol Metab* 93: 4774–4779.
9. Zhou SJ, Yelland L, McPhee AJ, Quinlivan J, Gibson RA, Makrides M (2012) Fish-oil supplementation in pregnancy does not reduce the risk of gestational diabetes or preeclampsia. *Am J Clin Nutr* 95:1378–1384.
10. Dodd JM, Turnbull D, McPhee AJ et al (2014) Antenatal lifestyle advice for women who are overweight or obese: LIMIT randomised trial. *BMJ* 348:g1285.
11. Poston L, Bell R, Croker H et al (2015) Effect of a behavioural intervention in obese pregnant women (the UPBEAT study): a multicentre, randomised controlled trial. *Lancet Diabetes Endocrinol* 3:767–777.
12. Yin YN, Li XL, Tao TJ, Luo BR, Liao SJ (2014) Physical activity during pregnancy and the risk of gestational diabetes mellitus: a systematic review and meta-analysis of randomised controlled trials. *Br J Sports Med* 48:290–295.
13. Laitinen K, Poussa T, Isolauri E (2009) Probiotics and dietary counselling contribute to glucose regulation during and after pregnancy: a randomised controlled trial. *Br J Nutr* 101:1679–1687.
14. Wolff S, Legarth J, Vangsgaard K, Toubro S, Astrup A (2008) A randomized trial of the effects of dietary counseling on gestational weight gain and glucose metabolism in obese pregnant women. *Int J Obes (Lond)* 32:495–501.
15. Simmons D, Jelsma JG, Galjaard S et al (2015) Results from a European multicenter randomized trial of physical activity and/or healthy eating to reduce the risk of gestational diabetes mellitus: The DALI lifestyle pilot. *Diabetes Care* 38:1650–1656.
16. Phelan S (2010) Pregnancy: a “teachable moment” for weight control and obesity prevention. *Am J Obstet Gynecol* 202:e131–e13.
17. Han S, Middleton P, Crowther CA (2012) Exercise for pregnant women for preventing gestational diabetes mellitus. *Cochrane Database Syst Rev*, Issue 7, Art. no.: CD009021. doi: 10.1002/14651858.CD009021.pub2.
18. Caplan RH, Pagliara AS, Beguin EA, et al. Constant intravenous insulin infusion during labor and delivery in diabetes mellitus. *Diabetes Care*. 1982;5(1):6-10.
19. Bouvain M, Stan C, Irion O. Elective delivery in diabetic pregnant women. *Cochrane Database Syst Rev*. 2001;(2):CD001997.

20. Rouse DJ, Owen J, Goldenberg RL, Cliver SP. The effectiveness and costs of elective cesarean delivery for fetal macrosomia diagnosed by ultra sound. *JAMA*. 1996;276(18):1480-1486.
21. Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. *Diabetes Care*. 2002;25(10): 1862-1868.
22. Kim C, Herman WH, Vijan S. Efficacy and cost of postpartum screen ing strategies for diabetes among women with histories of gestational diabetes mellitus. *Diabetes Care*. 2007;30(5):1102-1106.
23. Knowler WC, Barrett-Connor E, Fowler SE, for the Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med*. 2002; 346(6):393-403.
24. Huang D, Liang M, Xu B, Chen S, Xiao Y, Liu H, et al. The association of insufficient gestational weight gain in women with gestational diabetes mellitus with adverse infant outcomes: a case-control study. *Front Public Health*. (2023) 11:1054626. doi: 10.3389/fpubh.2023.1054626.
25. Lu L, He L, Hu J, Li J. Association between very advanced maternal age women with gestational diabetes mellitus and the risks of adverse infant outcomes: a cohort study from the NVSS 2014–2019. *BMC Pregnancy Childbirth*. (2023) 23(1):158. doi: 10.1186/s12884-023-05449-0.
26. Salomon C et al. Gestational diabetes mellitus is associated with changes in the concentration and bioactivity of placenta-derived exosomes in maternal circulation across gestation. *Diabetes*. 2016;65(3):598-609.
27. Santovito D et al. Plasma exosome microRNA profiling unravels a new potential modulator of adiponectin pathway in diabetes: Effect of glycemic control. *J Clin Endocrinol Metab*. 2014;99(9):E1681-5.
28. Ehrlich S et al. Endocrine disruptors: A potential risk factor for gestational diabetes mellitus. *Am J Perinatol*. 2016;33(13):1313-8.
29. Buchanan, T.A., et al. 2003. Changes in insulin secretion and sensitivity during the development of type 2 diabetes after gestational diabetes in His panic women. *Diabetes*. 52(Suppl. 1):A34.
30. Buchanan, T.A., et al. 2000. Response of pancreatic B-cells to improved insulin sensitivity in women at high risk for type 2 diabetes. *Diabetes*. 49:782–788.
31. Buchanan, T.A., et al. 2002. Preservation of pancreatic B-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. *Diabetes*. 51:2769–2803.
32. Langer, O., Conway, D.L., Berkus, M.D., Xenakis, E.M., and Gonzales, O. 2000. A comparison of glyburide and insulin in women with gestational diabetes mellitus. *N. Engl. J. Med*. 343:1134–1138.
33. Diabetes Prevention Program Research Group. 2002. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N. Engl. J. Med*. 346:393–403.
34. Xiang, A.H., et al. 2004. Pharmacological treatment of insulin resistance at two different stages in the evolution of type 2 diabetes: impact on glucose tolerance and β -cell function. *J. Clin. Endocrinol. Metab*. 89:2846–2851.
35. Kjos, S.L., and Buchanan, T.A. 1999. Gestational diabetes mellitus. *N. Engl. J. Med*. 341:1749–1756.
36. Towner, D., et al. 1995. Congenital malformations in pregnancies complicated by non-insulin-depen dent diabetes mellitus: increased risk from poor maternal metabolic control but not from exposure to sulfonylurea drugs. *Diabetes Care*. 18:1446–1451.